SI
SI
discoversearch

Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2205 96 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2205I think that their bi-specific is not very alive, toooooo slowwwwwww!Miljenko Zuanic-September 13
2204Sometime before it reads out right? Also they haven't made much publicity oFelix B-September 12
2203<We need the oncology efforts to become more visible.> In time! In time?Miljenko Zuanic-September 11
2202I agree with your points, but the market is fickle! We need the oncology effoBiotech Jim-September 11
2201<Down to the $350- 375 area?> No, I do not think so! Praluent IP will prMiljenko Zuanic-September 11
2200Competition is the name of the game. <So, severe correction is...???????? ..Biotech Jim-September 11
2199Surprice???!!! finance.yahoo.com So, what trigger SNY rush for more REGN sharesMiljenko Zuanic-September 11
2198Yes, it is distraction for investors.Miljenko Zuanic-September 7
2197And should come in cheaper due to not being a biologic right?Felix B-September 7
2196Possibility of REGN getting this too? I would imagine most practitioners would Felix B-September 7
2195Very comparative to Dupi (in AD): prnewswire.comMiljenko Zuanic-September 7
2194Anyone have access to this? statnews.comFelix B-August 31
2193Right in time with CAR-T approval: roche.comMiljenko Zuanic-August 30
2192Another question: When antibody R&D end, can Sanofi lunch hostile take-over?Miljenko Zuanic-August 29
2191And again today (70 K shares): secfilings.nasdaq.com Does ability to reach 30% Miljenko Zuanic-August 29
2190What is now this rush at Sanofi, 164.5 K shares (~$78-80 M), in two days: secfiMiljenko Zuanic-August 25
2189Praluent may stay on market, but MACE outcome trial has reduced chances to be siMiljenko Zuanic-August 23
2188Not sure what is worst, Montley or Seeking Alpha, then again where else do I go?Felix B-August 22
2187What's your guess on litigation outcome of Praulent? I think everyone has cFelix B-August 22
2186fool.com Idiots at Motley Fool have nothing better to talk, that the Street &quMiljenko Zuanic-August 22
2185Well, Eliquis is eliquis, bit of unick. RE: Dupi pharmpro.com I do not know whaMiljenko Zuanic-August 22
2184Thanks for sharingFelix B-August 9
2183More colour (review): epvantage.comMiljenko Zuanic-August 9
2182Is Roche making mistake(s)? Their bigger one was favoring PD-L1 instead PD1 (escMiljenko Zuanic-August 8
2181Did Sanofi made same mistake with Fasinumab, as it did with Eylea???? Well, 2Q bMiljenko Zuanic-August 4
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.